Drug profile · INN
chlorpromazine
LARGACTIL
chlorpromazine (LARGACTIL) is a d2-like dopamine receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.
Drug details — chlorpromazine
- US status
- approved
- Class
- —
- Route
- RECTAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
chlorpromazine (LARGACTIL) is a d2-like dopamine receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.
Key facts
Mechanism of action
D2-like dopamine receptor antagonist
Primary target: D2-like dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is chlorpromazine?
chlorpromazine (LARGACTIL) is a d2-like dopamine receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.
What is the brand name for chlorpromazine?
LARGACTIL is a marketed brand name for chlorpromazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of chlorpromazine?
chlorpromazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.